The Journal of pediatrics
-
The Journal of pediatrics · Mar 2014
Feasibility and safety of erythropoietin for neuroprotection after perinatal arterial ischemic stroke.
To perform a feasibility and safety study with recombinant human erythropoietin (rhEPO) in neonates with perinatal arterial ischemic stroke. ⋯ rhEPO in neonates with perinatal arterial ischemic stroke had no adverse effects on red blood cells, white blood cells, platelets counts, or coagulation. rhEPO, 3000 IU/kg in total, given during a 3-day period, appears to be a safe therapy. The beneficial effects remains to be demonstrated in a larger, randomized, double-blind, placebo-controlled trial.
-
The Journal of pediatrics · Mar 2014
Editorial CommentLearning more about dyslipidemia in childhood.